Fresh attention to an inverted bacterial defence mechanism shows how basic science can create platform ideas, while the distance to validated gene editing or antimicrobial products remains substantial
Newsflash:
Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends …
Fresh attention to an inverted bacterial defence mechanism shows how basic science can create platform ideas, while the distance to validated gene editing or antimicrobial products remains substantial
Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends …
Fresh attention to an inverted bacterial defence mechanism shows how basic science can create platform ideas, while the distance to validated gene editing or antimicrobial products remains substantial
Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
Fresh attention to an inverted bacterial defence mechanism shows how basic science can create platform ideas, while the distance to validated gene editing or antimicrobial products remains substantial
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends its programme costs
Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends its programme costs
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
A pivotal efficacy study and a separate G-CSF reduction trial could answer different questions, but market projections remain contingent on …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product …
Listen Now
The August 11 agreement gives Sentynl a route to license the oral neutrophil elastase inhibitor while Mereo advances regulatory planning in a genetically defined lung disorder
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, highlighting the regulatory tightrope in advanced therapeutics.
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward a fourth-quarter topline analysis
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?